Literature DB >> 32818258

Long-Term Disease Burden and Survivorship Issues After Surgery and Radiotherapy of Intracranial Meningioma Patients.

Amir H Zamanipoor Najafabadi1,2, Pim B van der Meer2, Florien W Boele3,4, Martin J B Taphoorn2,5, Martin Klein6, Saskia M Peerdeman7, Wouter R van Furth1, Linda Dirven2,5.   

Abstract

BACKGROUND: Many intracranial meningioma patients have an impaired health-related quality of life (HRQoL) and neurocognitive functioning up to 4 yr after intervention.
OBJECTIVE: To assess the long-term (≥5 yr) disease burden of meningioma patients.
METHODS: In this multicenter cross-sectional study, patients ≥5 yr after intervention (including active magnetic resonance imaging (MRI) surveillance) were included and assessed for HRQoL (Short-Form Health Survey 36), neurocognitive functioning (neuropsychological assessment), anxiety and depression (Hospital Anxiety and Depression Scale), and work productivity (Short Form-Health and Labour Questionnaire). Multivariable and propensity score regression analyses were used to compare patients and controls, and different treatment strategies corrected for possible confounders. Clinically relevant differences were reported.
RESULTS: At a median of 9 yr follow-up after intervention, meningioma patients (n = 190) reported more limitations due to physical (difference 12.5 points, P = .008) and emotional (13.3 points, P = .002) health problems compared with controls. Patients also had an increased risk to suffer from anxiety (odds ratio [OR]: 2.6, 95% CI: 1.2-5.7) and depression (OR: 3.7, 95% CI: 1.3-10.5). Neurocognitive deficits were found in 43% of patients. Although postoperative complications, radiotherapy, and reresection were associated with worse verbal memory, attention, and executive functioning when compared to patients resected once, the only clinically relevant association was between reresection and worse attention (-2.11, 95% CI: -3.52 to -0.07). Patients of working age less often had a paid job (48%) compared with the working-age Dutch population (72%) and reported more obstacles at work compared with controls.
CONCLUSION: In the long term, a large proportion of meningioma patients have impaired HRQoL, neurocognitive deficits, and high levels of anxiety or depression. Patients treated with 1 resection have the best neurocognitive functioning. © Congress of Neurological Surgeons 2020.

Entities:  

Keywords:  Anxiety; Cognitive function; Depression; Meningioma; Quality of life

Year:  2020        PMID: 32818258     DOI: 10.1093/neuros/nyaa351

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  4 in total

1.  Incidence trends and survival analysis of atypical meningiomas: a population-based study from 2004 to 2018.

Authors:  Matthew J Recker; Cathleen C Kuo; Dheerendra Prasad; Kristopher Attwood; Robert J Plunkett
Journal:  J Neurooncol       Date:  2022-07-11       Impact factor: 4.506

Review 2.  Single session versus multisession stereotactic radiosurgery for the management of intracranial meningiomas: a systematic review and meta-analysis.

Authors:  Othman Bin-Alamer; Nada Alnefaie; Jumanah Qedair; Adhiraj Chaudhary; Hana Hallak; Arif Abdulbaki; Arka N Mallela; Paolo Palmisciano; Zachary C Gersey; Andrew D Legarreta; Mohamed A Labib; Gabriel Zada; Jason P Sheehan; William T Couldwell; L Dade Lunsford; Hussam Abou-Al-Shaar
Journal:  J Neurooncol       Date:  2022-08-17       Impact factor: 4.506

3.  The long-term caregiver burden in World Health Organization grade I and II meningioma: It is not just the patient.

Authors:  Amir H Zamanipoor Najafabadi; Pim B van der Meer; Florien W Boele; Martin J B Taphoorn; Martin Klein; Saskia M Peerdeman; Wouter R van Furth; Linda Dirven
Journal:  Neurooncol Adv       Date:  2020-12-05

4.  Determinants and predictors for the long-term disease burden of intracranial meningioma patients.

Authors:  Amir H Zamanipoor Najafabadi; Pim B van der Meer; Florien W Boele; Martin J B Taphoorn; Martin Klein; Saskia M Peerdeman; Wouter R van Furth; Linda Dirven
Journal:  J Neurooncol       Date:  2020-10-19       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.